StockNews.AI
IONS
StockNews.AI
181 days

Ionis reports fourth quarter and full year 2024 financial results

1. Ionis launches TRYNGOLZA, marking a new commercial stage. 2. Three more independent medicines expected in next three years.

Earnings
+1.91%Current Return
VS
-0.43%S&P 500
$31.9502/19 07:22 AM EDTEvent Start
$32.5602/20 02:06 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The successful launch of TRYNGOLZA establishes Ionis' commercial capabilities, boosting investor confidence.

How important is it?

The launch of a new drug and future prospects can significantly influence IONS stock valuation.

Why Long Term?

Anticipated new drug launches can significantly increase market share and revenues over time.

Related Companies

IONS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Over the next three years, we expect three more.

Related News